您当前的位置:
首页 >
文章列表页 >
Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
- MMR 2024年11卷第1期 页码:98-114
DOI: 10.1186/s40779-023-00455-x
移动端阅览
HTML全文
图( 3 ) 表( 0 )
参考文献
出版信息
数据统计
43
浏览量
21
下载量
0
CSCD
文章被引用时,请邮件提醒。
提交
工具集
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
相关文章
Bioengineered exosomal-membrane-camouflaged abiotic nanocarriers: neurodegenerative diseases, tissue engineering and regenerative medicine
Activated Drp1 regulates p62-mediated autophagic flux and aggravates inflammation in cerebral ischemia-reperfusion via the ROS-RIP1/RIP3-exosome axis
Activation of systemic immune effectors and induction of cytokine production by direct intratumoral injection of IL-2 DNA liposome
Metabolic syndrome and risk of sepsis and sepsis-related mortality: evidence from two large prospective cohort studies
Immune microenvironment dynamics in pregnant patients with concomitant autoimmune diseases: mechanisms, challenges, and clinical significance
相关作者
Guang-Long Ma
Ana Cláudia Paiva-Santos
Miguel Pereira-Silva
Joana Lopes
Daniela Lopes
Diana Peixoto
Navid Rabiee
Omid Moradi
相关机构
Centre for Cancer Immunology, Faculty of Medicine, University of Southampton
School of Engineering, Institute for Bioengineering, the University of Edinburgh
Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University Shanghai Medical College
Integrated Composites Laboratory (ICL), Department of Mechanical and Construction Engineering, Northumbria University
Department of Chemistry, Shahr-e-Qods Branch, Islamic Azad University

